Fig. 3

The Kaplan–Meier survival analysis of NSCLC patients. Patients expressing CD68 had better overall survival than patients who did not (OS rate, 78.2% vs. 68.6%, log rank p = 0.023) (a), while CD163 was not associated with patient survival (b). Patients with a high M2 ratio (CD163/CD68) had significantly shorter overall survival than patients with a low M2 ratio (OS rate, 68.4% vs. 78.3%, log rank p = 0.023) (c). There were no meaningful overall survival differences for VEGF-A (d) and VEGF-C (e) expression in NSCLC patients